FIELD: chemistry.SUBSTANCE: invention relates to a new compound of formula (I) or a pharmaceutically acceptable salt thereof. In formula (I)Q is 6-member heteroaryl containing one or two heteroatoms selected from N； W is selected from N and CН； Z is selected from N and CR6； R1 is selected from heterocyclyl-C1-4 alkyl, where heterocyclyl is 6–12-member mono- or bicyclic ring containing one or two nitrogen atoms or one or two nitrogen atoms and one oxygen atom, and alkyl and heterocyclyl are unsubstituted or substituted with at least one substitute, such as one, two, three or four substitutes independently selected from RX； each R2 is hydrogen； each R3 is independently selected from hydrogen and C1-6 alkyl, where alkyl is unsubstituted or substituted with one, two, three or four substitutes independently selected from RX； or two R3 together with carbon atoms, to which they are bonded, form 3–7-member cyclic ring not containing additional heteroatoms and optionally substituted with 1, 2 or 3 groups RX； R4 is selected from hydrogen and halogen； each R5 is hydrogen； each R6 is independently selected from hydrogen and fluorine； each RX is independently selected from C1-6 alkyl, 6-member heterocyclyl containing two nitrogen atoms, halogen, -NRa1Rb1 and -ORa1, where alkyl and heterocyclyl are unsubstituted or substituted with at least one substitute, such as one, two, three or four substitutes independently selected from RY； each Ra1 and each Rb1 are independently selected from hydrogen and C1-6 alkyl； RY is independently selected from C1-10 alkyl； m is 2 or 3； n is selected from 0, 1 and 2； p is selected from 0, 1, 2 and 3； q is selected from 1, 2 and 3.EFFECT: compounds have cyclin-dependent kinase 4/6 (CDK4/6) inhibitor properties and can be used for treating CDK4/6 related diseases, for example, for treating proliferative diseases.23 cl, 6 tbl, 169 exИзобретение относится к новому соединению формулы (I) или его фармацевтически приемлемой соли. Соединения обладают свойст
